Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYCS | P99999 | 3/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651766 | 1.00 | TOP1 (0.41) | TOP1LMNAALDH1A1MAPTCYCS | |
| SCHEMBL24221290 | 0.92 | ADORA2A (0.37) | TOP1LMNAALDH1A1MAPTCYCS | |
| SCHEMBL18917432 | 0.89 | TOP1 (0.51) | TOP1LMNAALDH1A1MAPTCYCS | |
| SCHEMBL19718153 | 0.79 | PPARG (0.52) | CYCS | |
| SCHEMBL29831314 | 0.79 | PPARG (0.52) | CYCS | |
| SCHEMBL17651811 | 0.78 | TOP1 (0.43) | TOP1CYCSTERTDHODH | |
| SCHEMBL17651778 | 0.78 | TOP1 (0.43) | TOP1CYCSTERTDHODH | |
| SCHEMBL10523963 | 0.77 | TOP1 (0.60) | TOP1LMNACYCSABCG2TERT | |
| SCHEMBL30081962 | 0.75 | TERT (0.49) | MAPTABCG2TERT | |
| SCHEMBL433807 | 0.75 | TERT (0.49) | MAPTABCG2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403127-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2025-09-02 | — | — | US | disclosed |
| EP-3201201-B1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2022-01-26 | — | — | EP | disclosed |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2019-10-29 | — | — | US | disclosed |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2019-10-29 | — | — | US | disclosed |
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-02-08 | — | — | US | disclosed |
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-02-08 | — | — | US | disclosed |
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-02-08 | — | — | US | disclosed |
| EP-3201201-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | biolitec unternehmensbeteiligungs II AG (AT) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016051361-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016051361-A1 | SPECIFICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036284-A1 | SPECIFICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PHOTODYNAMIC THERAPY | DHPS, DDT, PPOX | TOP1 2038/4885LMNA 3830/4885ALDH1A1 2965/4885 |
| US-12403127-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | DHPS, DDT, PPOX | TOP1 2038/4885LMNA 3830/4885ALDH1A1 2965/4885 |
| US-10456375-B2 | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy | DHPS, DDT, PPOX | TOP1 2038/4885LMNA 3830/4885ALDH1A1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.